Isavuconazol-Register

The isavuconazole registry is a multicentre, retrospective study in Germany investigating the use of isavuconazole vs. voriconazole and/or liposomal amphotericin B in possible, probable and proven invasive aspergillosis (IA) and mucormycosis (IM). Patients with underlying haematological/oncological diseases who were treated for IA or IM between 2016 and 2021 were included. The aim is to analyse epidemiological factors as well as health economic aspects in the real-world setting. The study center in Frankfurt participated in the trial, while overall responsibility for the project was hold by the University Hospital Cologne.

This study is supported by an unrestricted research grant from Pfizer Pharma GmbH (Germany).